PDEX
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 15.43, Graham Number $31.55, Intrinsic Value $65.81
- P/E is low relative to healthcare sector average
- Price is below intrinsic value
- Price is significantly above Graham Number
- P/B is relatively high
Ref Revenue Growth 11.10%, Forward P/E 25.53
- Steady 11% revenue growth
- Forward P/E expansion suggests earnings headwinds
Ref Historical Price Performance
- Strong 3Y (+227.7%) and 5Y (+100.7%) price appreciation
- Recent 6M surge of 120%
- 1Y return is slightly negative (-14.2%)
Ref Piotroski F-Score, Debt/Equity, Current Ratio
- Piotroski F-Score 6/9 (Stable)
- Current Ratio 4.03
- Debt/Equity 0.27
- Altman Z-Score not provided
Ref Dividend Yield N/A
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PDEX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PDEX
Pro-Dex, Inc.
Primary
|
+100.7% | +227.7% | -14.2% | +120.0% | +5.2% | +3.4% |
|
NNOX
Nano-X Imaging Ltd.
Peer
|
-92.8% | -63.4% | -47.9% | -40.0% | -4.6% | +7.4% |
|
INGN
Inogen, Inc.
Peer
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
|
LFMD
LifeMD, Inc.
Peer
|
-74.2% | +107.8% | -30.3% | -43.8% | -14.5% | -1.1% |
|
LFCR
Lifecore Biomedical, Inc.
Peer
|
-52.8% | +24.4% | -17.0% | -26.9% | -30.2% | +23.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PDEX
Pro-Dex, Inc.
|
BULLISH | $171.58M | 15.43 | 30.9% | 15.7% | $52.6 | |
|
NNOX
Nano-X Imaging Ltd.
|
BEARISH | $171.89M | - | -34.8% | -% | $2.47 | Compare |
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | Compare |
|
LFMD
LifeMD, Inc.
|
BEARISH | $166.47M | - | -131.2% | 7.4% | $3.47 | Compare |
|
LFCR
Lifecore Biomedical, Inc.
|
BEARISH | $178.02M | - | -% | -23.8% | $4.75 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-22 | DOMINGO ANGELITA REBAMONTAN | Director | Stock Award | 18 | $618 |
| 2025-11-21 | PHILP KATRINA MARIE KRAMER | Director | Stock Award | 3,100 | $101,397 |
| 2025-11-20 | CABILLOT RAYMOND E | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,000 | - |
| 2025-11-20 | HOVDA DAVID C | Director | Stock Award | 1,000 | - |
| 2025-11-20 | CHARLTON ALISHA K | Chief Financial Officer | Stock Award | 1,000 | - |
| 2025-11-20 | SWENSON NICHOLAS JOHN | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,000 | - |
| 2025-11-20 | FARRELL WILLIAM JAMES III | Director | Stock Award | 1,000 | - |
| 2025-11-20 | PHILP KATRINA MARIE KRAMER | Director | Stock Award | 1,000 | - |
| 2025-11-20 | DOMINGO ANGELITA REBAMONTAN | Director | Stock Award | 1,000 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
PDEX filed its 10-Q on January 29, 2026, which includes disclosures regarding the unregistered sale of equity securities. While specific financial metrics were not provided in the excerpt, the filing identifies the existence of operational risk factors and recent capital-raising activities.
Past News Coverage
Recent headlines mentioning PDEX from our newsroom.